Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 26973 | 8.15 |
09:34 ET | 12685 | 8.11 |
09:36 ET | 8332 | 8.175 |
09:38 ET | 6277 | 8.1699 |
09:39 ET | 1050 | 8.16 |
09:41 ET | 3560 | 8.16 |
09:43 ET | 14283 | 8.14 |
09:45 ET | 1259 | 8.19 |
09:48 ET | 3415 | 8.095 |
09:50 ET | 717 | 8.1 |
09:52 ET | 1940 | 8.1 |
09:54 ET | 16857 | 8.09 |
09:56 ET | 1205 | 8.04 |
09:57 ET | 2100 | 8.05 |
09:59 ET | 13890 | 8.11 |
10:01 ET | 5021 | 8.07 |
10:03 ET | 7670 | 8.0772 |
10:06 ET | 5977 | 8.07 |
10:08 ET | 6409 | 8.195 |
10:10 ET | 28401 | 8.08 |
10:12 ET | 6288 | 8.16 |
10:14 ET | 2562 | 8.1 |
10:15 ET | 4251 | 8.075 |
10:17 ET | 5331 | 8.055 |
10:19 ET | 3520 | 8.09 |
10:21 ET | 2473 | 8.095 |
10:24 ET | 1701 | 8.12 |
10:26 ET | 6163 | 8.1 |
10:28 ET | 3454 | 8.125 |
10:30 ET | 2863 | 8.15 |
10:32 ET | 5088 | 8.089 |
10:33 ET | 2240 | 8.085 |
10:35 ET | 5964 | 8.1354 |
10:37 ET | 2483 | 8.1 |
10:39 ET | 3132 | 8.12 |
10:42 ET | 2809 | 8.1 |
10:44 ET | 5254 | 8.12 |
10:46 ET | 2793 | 8.1 |
10:48 ET | 11567 | 8.09 |
10:50 ET | 5879 | 8.025 |
10:51 ET | 6660 | 8.07 |
10:53 ET | 2095 | 8.08 |
10:55 ET | 5125 | 8.11 |
10:57 ET | 7440 | 8.095 |
11:00 ET | 6811 | 8.11 |
11:02 ET | 3865 | 8.13 |
11:04 ET | 13156 | 8.105 |
11:06 ET | 6912 | 8.09 |
11:08 ET | 1864 | 8.09 |
11:09 ET | 6404 | 8.09 |
11:11 ET | 1774 | 8.09 |
11:13 ET | 22616 | 8.08 |
11:15 ET | 2200 | 8.1 |
11:18 ET | 990 | 8.09 |
11:20 ET | 3497 | 8.055 |
11:22 ET | 5255 | 8.08 |
11:24 ET | 4215 | 8.1232 |
11:26 ET | 2375 | 8.12 |
11:27 ET | 200 | 8.105 |
11:29 ET | 1100 | 8.105 |
11:31 ET | 9628 | 8.175 |
11:33 ET | 26826 | 8.175 |
11:36 ET | 26515 | 8.2289 |
11:38 ET | 25539 | 8.14 |
11:40 ET | 4900 | 8.12 |
11:42 ET | 3740 | 8.12 |
11:44 ET | 2016 | 8.13 |
11:45 ET | 6338 | 8.11 |
11:47 ET | 2392 | 8.11 |
11:49 ET | 6802 | 8.1071 |
11:51 ET | 2482 | 8.09 |
11:54 ET | 1727 | 8.09 |
11:56 ET | 4176 | 8.11 |
11:58 ET | 7332 | 8.11 |
12:00 ET | 1237 | 8.14 |
12:02 ET | 716 | 8.1301 |
12:03 ET | 200 | 8.135 |
12:05 ET | 6292 | 8.17 |
12:07 ET | 2393 | 8.16 |
12:09 ET | 4789 | 8.1479 |
12:12 ET | 663 | 8.17 |
12:14 ET | 3847 | 8.15 |
12:16 ET | 4748 | 8.15 |
12:18 ET | 855 | 8.18 |
12:20 ET | 12864 | 8.155 |
12:21 ET | 2690 | 8.1599 |
12:23 ET | 1650 | 8.135 |
12:25 ET | 1094 | 8.14 |
12:27 ET | 4357 | 8.1 |
12:30 ET | 5725 | 8.105 |
12:32 ET | 7164 | 8.115 |
12:34 ET | 1607 | 8.1 |
12:36 ET | 8578 | 8.1 |
12:38 ET | 1750 | 8.15 |
12:39 ET | 1200 | 8.17 |
12:41 ET | 4700 | 8.1601 |
12:43 ET | 23657 | 8.16 |
12:45 ET | 12639 | 8.14 |
12:48 ET | 4286 | 8.17 |
12:50 ET | 2744 | 8.165 |
12:52 ET | 1200 | 8.18 |
12:54 ET | 8097 | 8.1601 |
12:56 ET | 6257 | 8.16 |
12:57 ET | 5345 | 8.19 |
12:59 ET | 8653 | 8.1851 |
01:01 ET | 4270 | 8.17 |
01:03 ET | 600 | 8.16 |
01:06 ET | 3200 | 8.18 |
01:08 ET | 1755 | 8.19 |
01:10 ET | 4860 | 8.2006 |
01:12 ET | 4844 | 8.19 |
01:14 ET | 883 | 8.185 |
01:15 ET | 13332 | 8.235 |
01:17 ET | 18984 | 8.26 |
01:19 ET | 8593 | 8.27 |
01:21 ET | 679 | 8.26 |
01:24 ET | 1799 | 8.27 |
01:26 ET | 2777 | 8.26 |
01:28 ET | 6486 | 8.29 |
01:30 ET | 800 | 8.29 |
01:32 ET | 833 | 8.28 |
01:35 ET | 6196 | 8.29 |
01:37 ET | 5398 | 8.285 |
01:39 ET | 2681 | 8.28 |
01:42 ET | 4239 | 8.3 |
01:44 ET | 1700 | 8.29 |
01:46 ET | 1369 | 8.31 |
01:48 ET | 1903 | 8.3199 |
01:50 ET | 5366 | 8.33 |
01:51 ET | 10475 | 8.33 |
01:53 ET | 23838 | 8.3201 |
01:55 ET | 1714 | 8.305 |
01:57 ET | 19131 | 8.26 |
02:00 ET | 7707 | 8.26 |
02:02 ET | 3748 | 8.23 |
02:04 ET | 500 | 8.22 |
02:06 ET | 5197 | 8.24 |
02:08 ET | 8237 | 8.24 |
02:09 ET | 2743 | 8.24 |
02:11 ET | 4873 | 8.225 |
02:13 ET | 15162 | 8.1924 |
02:15 ET | 6595 | 8.205 |
02:18 ET | 3699 | 8.225 |
02:20 ET | 2120 | 8.21 |
02:22 ET | 1278 | 8.2 |
02:24 ET | 1899 | 8.2101 |
02:26 ET | 1500 | 8.22 |
02:27 ET | 3177 | 8.23 |
02:29 ET | 1500 | 8.23 |
02:31 ET | 3155 | 8.225 |
02:33 ET | 4610 | 8.27 |
02:36 ET | 1686 | 8.25 |
02:38 ET | 1812 | 8.26 |
02:40 ET | 10515 | 8.268 |
02:42 ET | 1600 | 8.26 |
02:44 ET | 4429 | 8.25 |
02:45 ET | 2410 | 8.24 |
02:47 ET | 3624 | 8.27 |
02:49 ET | 955 | 8.26 |
02:51 ET | 820 | 8.275 |
02:54 ET | 1349 | 8.26 |
02:56 ET | 3239 | 8.27 |
02:58 ET | 5842 | 8.29 |
03:00 ET | 16485 | 8.23 |
03:02 ET | 9278 | 8.24 |
03:03 ET | 800 | 8.25 |
03:05 ET | 745 | 8.25 |
03:07 ET | 1174 | 8.27 |
03:09 ET | 3366 | 8.24 |
03:12 ET | 617 | 8.255 |
03:14 ET | 5968 | 8.27 |
03:16 ET | 6389 | 8.27 |
03:18 ET | 9544 | 8.2398 |
03:20 ET | 5170 | 8.21 |
03:21 ET | 6655 | 8.24 |
03:23 ET | 6696 | 8.27 |
03:25 ET | 4817 | 8.26 |
03:27 ET | 6446 | 8.3 |
03:30 ET | 9359 | 8.33 |
03:32 ET | 8782 | 8.33 |
03:34 ET | 5205 | 8.35 |
03:36 ET | 24029 | 8.3599 |
03:38 ET | 5684 | 8.32 |
03:39 ET | 15828 | 8.375 |
03:41 ET | 8953 | 8.368 |
03:43 ET | 12072 | 8.375 |
03:45 ET | 12729 | 8.38 |
03:48 ET | 27526 | 8.445 |
03:50 ET | 58253 | 8.45 |
03:52 ET | 12140 | 8.455 |
03:54 ET | 24766 | 8.445 |
03:56 ET | 37077 | 8.425 |
03:57 ET | 51956 | 8.375 |
03:59 ET | 84941 | 8.39 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.7B | -50.6x | --- |
Viking Therapeutics Inc | 5.7B | -55.9x | --- |
Madrigal Pharmaceuticals Inc | 5.9B | -12.0x | --- |
BridgeBio Pharma Inc | 5.4B | -8.6x | --- |
Cytokinetics Inc | 6.1B | -10.0x | --- |
Nuvalent Inc | 5.1B | -32.3x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.96 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -50.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.